Immunoregulatory role of IL-38 in rheumatoid arthritis: integrated analysis of pro-inflammatory cytokine interactions, HLA-DRB1 and PTPN22 gene expression, and treatment-related variations

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by aberrant cytokine signaling and genetic predisposition. Recent evidence has emerged linking Interleukin-38 (IL-38), an IL-1 family member cytokine, to serving as a putative immunomodulatory mediator of inflammation. This study aimed to examine the role of IL-38 in rheumatoid arthritis and correlate it with inflammatory cytokines, clinical disease activity indices and RA susceptibility genes ( HLA-DRB1 and PTPN22 ) expression. A total of 140 subjects, including 70 rheumatoid arthritis (RA) patients and 70 healthy controls (HC), were included. Clinical parameters were gathered (disease duration, DAS28-ESR, ESR, pain score, tender joint count and swollen joint count). Serum levels of IL-38, IL-6, IL-17 A, TNF-α, RF (rheumatoid factor), anti-CCP antibodies and complement C3 and C4 were measured using immunological assays. Expression levels of HLA-DRB1 and PTPN22 were measured using real-time quantitative PCR, by the 2⁻ΔΔCt method, through the use of GAPDH as an internal reference gene. Cytokine levels were correlated with clinical parameters and gene expression. Rheumatoid arthritis patients had increased serum IL-38 levels compared to healthy controls (154.77 ± 36.72 vs. 82.53 ± 6.75 pg/mL; p < 0.001) and these correlated weakly to moderately with indicators of disease activity, such as DAS28-ESR ( r = 0.40, p < 0.001), ESR ( r = 0.27, p = 0.023) and pain score ( r = 0.30, p = 0.013). IL-38 correlated weakly and positively with main inflammatory cytokines, especially IL-17 A ( r = 0.29, p = 0.014) and TNF-α ( r = 0.30, p = 0.012). Subgroup analysis showed significant differences in IL-38 levels among treatment groups ( p < 0.001) with the highest levels in patients treated with methotrexate and lowest levels observed in patients receiving biologic therapy. In rheumatoid arthritis patients, gene expression analysis showed a significant increase of HLA-DRB1 (4.24 ± 1.79 vs. 1.02 ± 0.21; p < 0.001) and decrease in PTPN22 expression (0.51 ± 0.17 vs. 1.01 ± 0.16; p < 0.001). Moreover, levels of IL-38 correlated weakly and positively with HLA-DRB1 expression ( r = 0.28, p = 0.020), whereas a moderate negative correlation was established for PTPN22 expression ( r = − 0.55, p < 0.001). IL-38 is weakly to moderately correlated with inflammatory cytokines, clinical disease activity and RA susceptibility gene expression, with the exception of a moderate inverse association with PTPN22. These results indicate that IL-38 might be a candidate immunological marker linked to inflammatory signaling systems and genetic susceptibility mechanisms in rheumatoid arthritis, warranting further validation in larger, longitudinal cohorts.

Authors

Institutions

Publication Details

Journal
BMC Rheumatology
Published
2026-11-18
DOI
https://doi.org/10.1186/s41927-026-00709-w
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immunoregulatory role of IL-38 in rheumatoid arthritis: integrated analysis of pro-inflammatory cytokine interactions, HLA-DRB1 and PTPN22 gene expression, and treatment-related variations

Ahmed Flayyih Hasan, Hiba Abdulameer Mohammed, Mohanad Salam Hussein, Ahmed M. Amshawee et al.
1 links
BMC Rheumatology
Rheumatoid Arthritis Research and Therapies
article

Immunoregulatory role of IL-38 in rheumatoid arthritis: integrated analysis of pro-inflammatory cytokine interactions, HLA-DRB1 and PTPN22 gene expression, and treatment-related variations

Ahmed Flayyih Hasan, Hiba Abdulameer Mohammed, Mohanad Salam Hussein, Ahmed M. Amshawee, Yasir Chnani, Mais Nameer Abdul-Samad, Rafid Abdulwahid Abdulkarrem
article en

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by aberrant cytokine signaling and genetic predisposition. Recent evidence has emerged linking Interleukin-38 (IL-38), an IL-1 family member cytokine, to serving as a putative immunomodulatory mediator of inflammation. This study aimed to examine the role of IL-38 in rheumatoid arthritis and correlate it with inflammatory cytokines, clinical disease activity indices and RA susceptibility genes ( HLA-DRB1 and PTPN22 ) expression. A total of 140 subjects, including 70 rheumatoid arthritis (RA) patients and 70 healthy controls (HC), were included. Clinical parameters were gathered (disease duration, DAS28-ESR, ESR, pain score, tender joint count and swollen joint count). Serum levels of IL-38, IL-6, IL-17 A, TNF-α, RF (rheumatoid factor), anti-CCP antibodies and complement C3 and C4 were measured using immunological assays. Expression levels of HLA-DRB1 and PTPN22 were measured using real-time quantitative PCR, by the 2⁻ΔΔCt method, through the use of GAPDH as an internal reference gene. Cytokine levels were correlated with clinical parameters and gene expression. Rheumatoid arthritis patients had increased serum IL-38 levels compared to healthy controls (154.77 ± 36.72 vs. 82.53 ± 6.75 pg/mL; p < 0.001) and these correlated weakly to moderately with indicators of disease activity, such as DAS28-ESR ( r = 0.40, p < 0.001), ESR ( r = 0.27, p = 0.023) and pain score ( r = 0.30, p = 0.013). IL-38 correlated weakly and positively with main inflammatory cytokines, especially IL-17 A ( r = 0.29, p = 0.014) and TNF-α ( r = 0.30, p = 0.012). Subgroup analysis showed significant differences in IL-38 levels among treatment groups ( p < 0.001) with the highest levels in patients treated with methotrexate and lowest levels observed in patients receiving biologic therapy. In rheumatoid arthritis patients, gene expression analysis showed a significant increase of HLA-DRB1 (4.24 ± 1.79 vs. 1.02 ± 0.21; p < 0.001) and decrease in PTPN22 expression (0.51 ± 0.17 vs. 1.01 ± 0.16; p < 0.001). Moreover, levels of IL-38 correlated weakly and positively with HLA-DRB1 expression ( r = 0.28, p = 0.020), whereas a moderate negative correlation was established for PTPN22 expression ( r = − 0.55, p < 0.001). IL-38 is weakly to moderately correlated with inflammatory cytokines, clinical disease activity and RA susceptibility gene expression, with the exception of a moderate inverse association with PTPN22. These results indicate that IL-38 might be a candidate immunological marker linked to inflammatory signaling systems and genetic susceptibility mechanisms in rheumatoid arthritis, warranting further validation in larger, longitudinal cohorts.

BMC Rheumatology
University of Baghdad (IQ), Mustansiriyah University (IQ), University of Babylon (IQ), Al-Farabi University (IQ), University of Hillah (IQ), Nahrain University (IQ)
Good health and well-being
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon